Interim Report 1 January – 31 March 2024
Positive profitability trend driven by Medtech "During the quarter, profitability strengthened in line with our priorities and organic sales increased by 4%. Labtech's sales performance was temporarily weaker, but the companies were largely able to defend their margins. Medtech delivered strong growth and it is gratifying to see a gradual improvement in profitability, driven in part by implemented improvement measures."Fredrik Dalborg, President and CEO AddLife´s interim report for Q1 2024 is now available online at the company website. The interim report can be downloaded in pdf